Literature DB >> 25240869

Recent developments in tubulin polymerization inhibitors: An overview.

Ramandeep Kaur1, Gurneet Kaur1, Rupinder Kaur Gill2, Richard Soni1, Jitender Bariwal3.   

Abstract

Microtubules are protein biopolymers formed through polymerization of heterodimers of α- and β-tubulins. Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles. Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery. A number of naturally occurring compounds such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymerization and depolymerization. During past few years, rapid development of the novel tubulin polymerization inhibitors has been witnessed. Diverse classes of chemical compounds from the natural as well as from the synthetic origin have been extensively studied. This review highlights the various classes of synthetically derived chemical compounds those have been reported in last few years as potential tubulin polymerization inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the brief SAR studies. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds to inhibit the tubulin polymerization.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Disruption of microtubules; Microtubules; Tubulin polymerization; Tubulin polymerization inhibitors

Mesh:

Substances:

Year:  2014        PMID: 25240869     DOI: 10.1016/j.ejmech.2014.09.051

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  55 in total

Review 1.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

Review 2.  Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.

Authors:  Zaki S Seddigi; M Shaheer Malik; A Prasanth Saraswati; Saleh A Ahmed; Ahmed O Babalghith; Hawazen A Lamfon; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-07-04       Impact factor: 3.597

3.  Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.

Authors:  Jing-De Wu; Ying-Jie Cui; Yi-Gang Zhou; Long-Qian Tang; Cheng-Mei Zhang; Zhao-Peng Liu
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.850

4.  Covalent modification of Cys-239 in β-tubulin by small molecules as a strategy to promote tubulin heterodimer degradation.

Authors:  Jianhong Yang; Yong Li; Wei Yan; Weimin Li; Qiang Qiu; Haoyu Ye; Lijuan Chen
Journal:  J Biol Chem       Date:  2019-04-02       Impact factor: 5.157

5.  Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.

Authors:  Anja C Bloom; Lewis H Bender; Shweta Tiwary; Lise Pasquet; Katharine Clark; Tianbo Jiang; Zheng Xia; Aizea Morales-Kastresana; Jennifer C Jones; Ian Walters; Masaki Terabe; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2019-07-16       Impact factor: 8.110

6.  Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-ones as Novel Tubulin Inhibitors.

Authors:  Li Jiang; Masuo Goto; Dong-Qing Zhu; Pei-Ling Hsu; Kang-Po Li; Mutian Cui; Xiaoyang He; Susan Lynne Morris-Natschke; Kuo-Hsiung Lee; Lan Xie
Journal:  ACS Med Chem Lett       Date:  2019-12-30       Impact factor: 4.345

7.  Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents.

Authors:  Qile Xu; Yueting Wang; Jingwen Xu; Maolin Sun; Haiqiu Tian; Daiying Zuo; Qi Guan; Kai Bao; Yingliang Wu; Weige Zhang
Journal:  ACS Med Chem Lett       Date:  2016-10-17       Impact factor: 4.345

8.  Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores).

Authors:  Khushbu Shah; Sudhir Raghavan; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Mol Graph Model       Date:  2018-02-20       Impact factor: 2.518

9.  Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization.

Authors:  Wenlong Li; Wen Shuai; Feijie Xu; Honghao Sun; Shengtao Xu; Hong Yao; Jie Liu; Hequan Yao; Zheying Zhu; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2018-09-25       Impact factor: 4.345

10.  Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.

Authors:  Sheng-Biao Wang; Xiao-Feng Wang; Bingjie Qin; Emika Ohkoshi; Kan-Yen Hsieh; Ernest Hamel; Mu-Tian Cui; Dong-Qing Zhu; Masuo Goto; Susan L Morris-Natschke; Kuo-Hsiung Lee; Lan Xie
Journal:  Bioorg Med Chem       Date:  2015-07-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.